Biora Therapeutics Valuation

Is 4ZU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4ZU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4ZU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4ZU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4ZU?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 4ZU. This is calculated by dividing 4ZU's market cap by their current preferred multiple.
What is 4ZU's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$10.85m

4ZU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	63x
Enterprise Value/EBITDA	-0.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4ZU's PS Ratio compare to its peers?

The above table shows the PS ratio for 4ZU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.7x
MDG1 Medigene	3.1x	16.1%	€23.8m
CNW co.don	0.7x	n/a	€6.5m
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
ECX Epigenomics	6.4x	n/a	€875.2k
4ZU Biora Therapeutics	12.6x	55.1%	€10.8m

Price-To-Sales vs Peers: 4ZU is expensive based on its Price-To-Sales Ratio (12.6x) compared to the peer average (4x).

Price to Earnings Ratio vs Industry

How does 4ZU's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 4ZU is expensive based on its Price-To-Sales Ratio (12.6x) compared to the European Biotechs industry average (8.9x).

Price to Sales Ratio vs Fair Ratio

What is 4ZU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4ZU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	12.6x
Fair PS Ratio	7.2x

Price-To-Sales vs Fair Ratio: 4ZU is expensive based on its Price-To-Sales Ratio (12.6x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4ZU forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€5.10	€88.84 +1,642.0%	53.8%	€136.68	€41.00	n/a	2
Oct ’25	€4.24	€88.84 +1,995.3%	53.8%	€136.68	€41.00	n/a	2
Sep ’25	€6.10	€88.84 +1,356.4%	53.8%	€136.68	€41.00	n/a	2
Aug ’25	€5.80	€94.87 +1,535.7%	45.6%	€138.17	€51.58	n/a	2
Jul ’25	€5.80	€94.87 +1,535.7%	45.6%	€138.17	€51.58	n/a	2
Jun ’25	€5.95	€94.87 +1,494.5%	45.6%	€138.17	€51.58	n/a	2
May ’25	€6.05	€94.87 +1,468.2%	45.6%	€138.17	€51.58	n/a	2
Apr ’25	€10.00	€259.29 +2,492.9%	79.9%	€466.35	€52.23	n/a	2
Mar ’25	€10.00	€259.29 +2,492.9%	79.9%	€466.35	€52.23	n/a	2
Feb ’25	€8.50	€259.29 +2,950.5%	79.9%	€466.35	€52.23	n/a	2
Jan ’25	€12.50	€259.29 +1,974.3%	79.9%	€466.35	€52.23	n/a	2
Dec ’24	€12.10	€259.29 +2,042.9%	79.9%	€466.35	€52.23	n/a	2
Nov ’24	€18.50	€492.37 +2,561.5%	74.3%	€949.30	€53.16	€5.10	3
Oct ’24	€20.20	€768.49 +3,704.4%	21.2%	€931.50	€605.48	€4.24	2
Sep ’24	€27.60	€768.49 +2,684.4%	21.2%	€931.50	€605.48	€6.10	2
Aug ’24	€35.20	€768.49 +2,083.2%	21.2%	€931.50	€605.48	€5.80	2
Jul ’24	€34.80	€768.49 +2,108.3%	21.2%	€931.50	€605.48	€5.80	2
Jun ’24	n/a	€768.49 0%	21.2%	€931.50	€605.48	€5.95	2
May ’24	n/a	€768.49 0%	21.2%	€931.50	€605.48	€6.05	2
Apr ’24	n/a	€768.49 0%	21.2%	€931.50	€605.48	€10.00	2
Mar ’24	n/a	€768.49 0%	21.2%	€931.50	€605.48	€10.00	2
Feb ’24	n/a	€768.49 0%	21.2%	€931.50	€605.48	€8.50	2
Jan ’24	€33.65	€1,248.13 +3,609.1%	20.0%	€1,497.75	€998.50	€12.50	2
Dec ’23	€54.88	€1,248.13 +2,174.5%	20.0%	€1,497.75	€998.50	€12.10	2
Nov ’23	€94.03	€1,248.13 +1,227.4%	20.0%	€1,497.75	€998.50	€18.50	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.